Alzheimers: Non-amyloid targets in drug development?
(Post Date: 4/2/14)
(Post Date: 4/2/14)
What non-amyloid targets should be pursued for Alzheimer's disease therapies? We put the question to three well-known researchers in the field: Bradley Hyman, MD, PhD, of Massachusetts General Hospital in Boston; John Trojanowski, MD, PhD, of the University of Pennsylvania in Philadelphia; and Richard J. Caselli, MD, of the Mayo Clinic in Scottsdale, Ariz. Their answers ranged from tau protein pathologies to apolipoprotein E to general neuroprotection.
No comments:
Post a Comment